← Leaderboards
Kenton Dodyan Fong
Savage Medical
$3,313,000
Attributed
$3,313,000
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.1M · FY2021–25$2.5M$1.9M$1.3M$625K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,313,000 · 3
By mechanism
R44$2,959,491 · 2
R43$353,509 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Rectal Cancer”
- Dustin A Deming · University Of Wisconsin-Madison$4,217,350
- Jesse Joshua Smith · Sloan-Kettering Inst Can Research$3,709,431
- Andrea Cercek · Sloan-Kettering Inst Can Research$3,322,416
- Susan Mazanec · Case Western Reserve University$3,043,651
- Fiona Ginty · General Electric Global Research Ctr$2,765,175
- Folasade Popoola May · University Of California Los Angeles$2,507,762
Research focus
Rectal CancerTechnologyOstomyQuality Of LifeS DiseaseSurgery OutcomeHealth Care CostsOperative Surgical ProceduresExcisionPsychologicIschemic Bowel DiseaseMorbidity - Disease RateMedical DeviceMedicalClinical TrialsDevicesCancer SurgeryMortalityCrohn&AposDiverticulitisCost SavingsColonInflammatory Bowel DiseasesTranslating
Grant awards (5)
Safety and Efficacy Trial of the ColoSeal ICD System for the Treatment of Diverticular Disease Patients$1,192,362
R44 · FY2025 · DK · contact PI
Safety and Efficacy Trial of the ColoSeal ICD System for the Treatment of Rectal Cancer Patients$928,967
R44 · FY2025 · CA · contact PI
Safety and Efficacy Trial of the ColoSeal ICD System for the Treatment of Rectal Cancer Patients$838,162
R44 · FY2024 · CA · contact PI
A Novel Device Alternative to Temporary Diverting Ostomies after Rectal Cancer Surgery$55,000
R43 · FY2022 · CA · contact PI
A Novel Device Alternative to Temporary Diverting Ostomies after Rectal Cancer Surgery$298,509
R43 · FY2021 · CA · contact PI